Health Care · Pharmaceutical Preparations

GERN GERON CORP SEC Filings & Insider Trading Activity 2026

company
CIK 886744113 filings
Russell 2000

GERN at a glance

GERON CORP (GERN, SEC CIK 886744) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding GERON CORP (GERN) shares worth $250.8 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Williams Timothy on November 16, 2026 of 12,000 shares at $0.94 per share.
  • In the last 90 days, GERN insiders reported 2 open-market purchases ($62K) and 0 open-market sales ($0) on Form 4, a net purchase of $62K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
2 buys · 0 sells
Net +$62K
13F holders
28 funds
$250.8M · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Biopharmaceutical company focused on cancer therapeutics development
  • No new products, services, or segments introduced or emphasized in this filing year
  • Continued emphasis on corporate governance with established Code of Conduct and Insider Trading Policy
  • No quantitative metrics disclosed in Business section; governance details referenced extensively to Proxy Statement
  • Unusual fact: Entire Business section replaced by governance, ethics, and reference to Proxy Statement, lacking typical operational details

Risk Factors

  • Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
  • Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
  • Supply chain risk: $60 million in manufacturing commitments for RYTELO requiring long lead-times and incurring cancellation penalties
  • Competitive risk: Potential market disruption if RYTELO commercialization fails or competitors advance alternative myelodysplastic syndrome treatments
  • Financial risk: $119.5 million long-term debt principal with covenants and maturity in 2029, plus $141 million net proceeds dilution risk from equity offerings

Management Discussion & Analysis

  • Risks focus on commercialization, regulatory approvals, clinical trial outcomes, manufacturing, and market acceptance of RYTELO (imetelstat)
  • Forward-looking risks include FDA/EC approval timelines, clinical trial delays, competitive pressures, and macroeconomic impacts on operations

AI summary of the GERN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly triggered clinical-development risk: IMpactMF Phase 3 discontinued in October 2026 after an independent DMC found overall survival endpoint unlikely
  • Most material commercial update: RYTELO revenue $169.4 million vs $135.6 million for nine months ended September 30, 2026 and 2025, respectively
  • Regulatory risk: FDA and EU approvals require long-term safety studies and alternative-dosing trials, with potential penalties or withdrawal for noncompliance
  • Near-term market risk: revised U.S. strategy targets high-volume earlier-line accounts and non-personal promotion after sales growth remained limited
  • Financial risk: $125.0 million Pharmakon term loan secured by substantially all assets, including intellectual property, with Tranche B and C no longer available

Management Discussion & Analysis

  • Q3 revenue $60.2M, up $13.0M YoY from $47.2M, driven by RYTELO product revenue
  • Net income $1.4M vs $18.4M loss YoY, operating margin 9.6% vs (29.4)%
  • RYTELO product revenue $60.1M, up $12.9M YoY, the only disclosed product line
  • Cash, equivalents, restricted cash and securities $339.4M vs $401.1M at December 31, 2025
  • Outlook: Germany availability expected by end-2026, Q4 gross-to-net adjustments expected in low to mid-twenties percentage range

AI summary of the GERN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Q3 2026 results for the quarter ended September 30, 2026
  • Business highlights included alongside quarterly financial results, with investor detail in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 RYTELO revenue $60.1M, up 5% sequentially and 27% year over year, signaling continued commercial adoption in LR-MDS
  • 2026 RYTELO revenue guidance maintained at mid-to-high end of $220M-$240M, while operating expense guidance reduced to $220M-$230M
Filed Oct 28, 2026Full analysis →

Item 8.01: Other Events

  • Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis
  • Clinical update may materially affect imetelstat approval prospects, development timelines, and Geron’s valuation

Item EX-99.1: Item EX-99.1

  • Phase 3 IMpactMF discontinued after independent DMC judged overall-survival endpoint unlikely to be met
  • Trial enrolled 327 relapsed/refractory myelofibrosis patients after JAK-inhibitor treatment
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 RYTELO revenue $57.5M, up 17% YoY and 11% sequentially, supporting continued commercial adoption
  • Ordering accounts increased 8% to approximately 1,575, while demand rose 5% sequentially

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Business highlights included in Exhibit 99.1 press release

AI summaries of GERN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GERN

Don't miss the next GERN filing

  • Alerts as it files. A push when GERN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GERN, by share count.
  • Ask anything. An AI agent that reads every GERN filing and answers with sources.

GERN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Williams TimothyBuyNov 16, 2026$0.94
Semerjian HaroutBuyNov 13, 2026$0.95
Spiegel Robert J.ASep 30, 2026$1.23
Spiegel Robert J.AJun 30, 2026$1.28
McDonald John FAMay 20, 2026-
Bir Dawn CarterAMay 20, 2026-
O'Farrell Elizabeth G.AMay 20, 2026-
Molineaux SusanAMay 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$193.9M-$173.7M-$68.6M
Net Income-$184.1M-$174.6M-$83.5M
Balance Sheet
Total Assets$394.1M$593.8M$570.5M
Equity$247.9M$280.3M$225.9M
ROE-74.3%-62.3%-37.0%
Per Share
EPS$-0.32$-0.27$-0.13
Cash Flow
Operating CF-$167.7M-$218.6M-$111.0M
CapEx$830K$680K-

Source: XBRL data in GERON CORP (GERN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GERN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GERN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$250.8M
Q2 202630$281.3M
Q1 202629$279.2M
Q4 202526$233.8M
Q3 202526$265.4M
Q2 202524$251.6M
Q1 202523$218.0M
Q4 202420$360.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GERN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 16, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 28, 2026Analysis-
4Oct 1, 2026--
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 1, 2026--
8-KMay 27, 2026Analysis
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
10-QMay 6, 2026Analysis
4Apr 14, 2026--
4Apr 1, 2026--
8-KMar 26, 2026--
4Mar 26, 2026--
4Mar 26, 2026--
SC 13GMar 3, 2026-
10-KMar 2, 2026Analysis
8-KFeb 25, 2026Analysis-

Related Health Care companies

All Health Care →

GERN SEC filings: frequently asked questions

Are GERN insiders buying or selling?

In the last 90 days, GERON CORP (GERN) officers, directors and 10% owners reported 2 open-market purchases worth $62,105 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GERN stock?

As of September 30, 2026, the largest GERON CORP (GERN) holders among the 13F filers tracked by SignalX were BlackRock ($62.2 million), State Street Corp ($39.2 million), Vanguard Capital Management LLC ($34.0 million), Citadel Advisors LLC ($29.9 million), Goldman Sachs Group ($16.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in GERN's latest 10-K?

In the 10-K filed March 2, 2026, GERON CORP (GERN) flagged: Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation. Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations. (AI summary of the Risk Factors section.)

What did GERN report in its latest 8-K?

GERON CORP (GERN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 2026 results for the quarter ended September 30, 2026.

What are the latest GERN SEC filings?

GERON CORP (GERN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 16, 2026.

What is GERN's SEC CIK number?

GERON CORP (GERN)'s SEC Central Index Key (CIK) is 886744. EDGAR lists every GERN filing under that number.

Ask anything about GERN

The research agent reads GERN's filings, financials, insider trades and 13F holders, then answers with sources.